Boston Scientific Corp
NYSE:BSX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
55.99
91.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Boston Scientific Corp
Wall Street
Price Targets
BSX Price Targets Summary
Boston Scientific Corp
According to Wall Street analysts, the average 1-year price target for
BSX
is 102.58 USD
with a low forecast of 86.86 USD and a high forecast of 121.8 USD.
BSX Last Price Targets
Boston Scientific Corp
The latest public price target was made on Oct 24, 2024 by
Kristen Stewart
from
C.L. King
,
who expects
BSX
stock to
drop by 1%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Kristen Stewart
C.L. King
|
90
USD
Downside 1% |
2 months ago
Oct 24, 2024
|
CL King Reiterates Buy Rating on Boston Scientific (BSX)
StreetInsider
|
Shagun Singh
RBC Capital
|
98
USD
Upside 8% |
2 months ago
Oct 24, 2024
|
Boston Scientific (BSX) PT Raised to $98 at RBC Capital
StreetInsider
|
William Plovanic
Canaccord Genuity
|
98
USD
Upside 8% |
2 months ago
Oct 21, 2024
|
Boston Scientific (BSX) PT Raised to $98 at Canaccord Genuity
StreetInsider
|
Rick Wise
Stifel Nicolaus
|
100
USD
Upside 10% |
2 months ago
Oct 18, 2024
|
Boston Scientific (BSX) PT Raised to $100 at Stifel
StreetInsider
|
David Rescott
Robert W. Baird
|
100
USD
Upside 10% |
2 months ago
Oct 15, 2024
|
Boston Scientific (BSX) PT Raised to $100 at Baird
StreetInsider
|
Richard Newitter
Truist Financial
|
100
USD
Upside 10% |
2 months ago
Oct 14, 2024
|
Boston Scientific price target raised to $100 from $90 at Truist
TheFly
|
Matt O'Brien
Piper Sandler
|
90
USD
Downside 1% |
3 months ago
Sep 19, 2024
|
Piper Sandler Reiterates Overweight Rating on Boston Scientific (BSX)
StreetInsider
|
Pito Chickering
Deutsche Bank
|
78
USD
Downside 14% |
4 months ago
Jul 25, 2024
|
Boston Scientific price target raised to $78 from $73 at Deutsche Bank
TheFly
|
|
Marie Thibault
BTIG
|
84
USD
Downside 8% |
5 months ago
Jul 15, 2024
|
Boston Scientific price target raised to $84 from $80 at BTIG
TheFly
|
|
William Plovanic
Canaccord Genuity
|
83
USD
Downside 9% |
6 months ago
Jun 18, 2024
|
Canaccord Genuity Boston Scientific (BSX) at Buy following Silk Road Medical (SILK) deal
StreetInsider
|
|
David Rescott
Robert W. Baird
|
90
USD
Downside 1% |
6 months ago
Jun 11, 2024
|
Boston Scientific (BSX) PT Raised to $90 at Baird
StreetInsider
|
David Roman
Goldman Sachs
|
90
USD
Downside 1% |
6 months ago
May 30, 2024
|
Goldman Sachs Starts Boston Scientific (BSX) at Buy
StreetInsider
|
John Eade
Argus Research
|
95
USD
Upside 5% |
6 months ago
May 28, 2024
|
Boston Scientific (BSX) PT Raised to $95 at Argus
StreetInsider
|
|
Shagun Singh
RBC Capital
|
82
USD
Downside 10% |
7 months ago
Apr 25, 2024
|
Boston Scientific (BSX) PT Raised to $82 at RBC Capital
StreetInsider
|
Vijay Kumar
Evercore ISI
|
78
USD
Downside 14% |
7 months ago
Apr 25, 2024
|
Boston Scientific price target raised to $78 from $72 at Evercore ISI
TheFly
|
Lawrence Biegelsen
Wells Fargo
|
82
USD
Downside 10% |
7 months ago
Apr 25, 2024
|
Boston Scientific (BSX) PT Raised to $82 at Wells Fargo
StreetInsider
|
Steven Lichtman
Oppenheimer
|
77
USD
Downside 15% |
7 months ago
Apr 25, 2024
|
Boston Scientific (BSX) PT Raised to $77 at Oppenheimer
StreetInsider
|
|
Richard Newitter
Truist Financial
|
86
USD
Downside 5% |
7 months ago
Apr 25, 2024
|
Boston Scientific (BSX) PT Raised to $86 at Truist Securities
StreetInsider
|
Anthony Petrone
Mizuho Securities
|
85
USD
Downside 6% |
7 months ago
Apr 25, 2024
|
Boston Scientific (BSX) PT Lowered to $85 at Mizuho
StreetInsider
|
|
David Rescott
Robert W. Baird
|
84
USD
Downside 8% |
7 months ago
Apr 25, 2024
|
Boston Scientific (BSX) PT Raised to $84 at Baird
StreetInsider
|
|
Pito Chickering
Deutsche Bank
|
73
USD
Downside 20% |
8 months ago
Apr 24, 2024
|
Boston Scientific price target raised to $73 from $63 at Deutsche Bank
TheFly
|
|
Rick Wise
Stifel Nicolaus
|
83
USD
Downside 9% |
8 months ago
Apr 24, 2024
|
Boston Scientific (BSX) PT Raised to $83 at Stifel
StreetInsider
|
|
Marie Thibault
BTIG
|
80
USD
Downside 12% |
8 months ago
Apr 24, 2024
|
Boston Scientific (BSX) PT Raised to $80 at BTIG
StreetInsider
|
|
Marie Thibault
BTIG
|
74
USD
Downside 19% |
8 months ago
Apr 15, 2024
|
Boston Scientific price target raised to $74 from $72 at BTIG
TheFly
|
|
John Eade
Argus Research
|
80
USD
Downside 12% |
8 months ago
Apr 3, 2024
|
Boston Scientific (BSX) PT Raised to $80 at Argus
StreetInsider
|
Unknown Analyst
J.P. Morgan
|
55
USD
Downside 39% |
1 year ago
Feb 2, 2023
|
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $55
Benzinga
|
Unknown Analyst
Needham
|
53
USD
Downside 42% |
1 year ago
Feb 2, 2023
|
Needham Maintains Buy on Boston Scientific, Raises Price Target to $53
Benzinga
|
Operating Income
Forecast
Operating Income Estimate
Boston Scientific Corp
For the last 8 years the
compound annual growth rate for
Boston Scientific Corp's operating income is
13%.
The projected
CAGR
for the next 4 years is
28%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BSX's stock price target?
Price Target
102.58
USD
According to Wall Street analysts, the average 1-year price target for
BSX
is 102.58 USD
with a low forecast of 86.86 USD and a high forecast of 121.8 USD.
What is Boston Scientific Corp's Revenue forecast?
Projected CAGR
12%
For the last 8 years the
compound annual growth rate for
Boston Scientific Corp's revenue is
8%.
The projected
CAGR
for the next 4 years is
12%.
What is Boston Scientific Corp's Operating Income forecast?
Projected CAGR
28%
For the last 8 years the
compound annual growth rate for
Boston Scientific Corp's operating income is
13%.
The projected
CAGR
for the next 4 years is
28%.
What is Boston Scientific Corp's Net Income forecast?
Projected CAGR
35%
The
compound annual growth rate
of Boston Scientific Corp's net income for the next 4 years is
35%.
You don't have any saved screeners yet
